Tag: Cholesterol

  • Enlicitide Shows Lasting LDL Cholesterol Reductions

    Enlicitide Shows Lasting LDL Cholesterol Reductions

    Enlicitide Shows Sustained LDL Lowering in Longer Follow-Up

    Oral cholesterol treatment is back in the spotlight after longer-term data suggested that LDL cholesterol reductions with enlicitide were maintained beyond the original trial period. In a Pharmacy Times interview about CORALreef Extension, investigator Christie Ballantyne reported sustained LDL lowering and no new safety signals during the additional follow-up (Pharmacy Times).

    The update follows an earlier regulatory milestone: the FDA lists Lipfendra, whose active ingredient is enlicitide decanoate, as approved on July 15, 2026, to reduce LDL cholesterol (FDA). The latest story therefore concerns durability after earlier studies, not a newly announced November approval (Pharmacy Times).

    What the extension adds

    The extension allowed eligible participants from earlier CORALreef studies to continue into an open-label phase, meaning the treatment was known rather than concealed (Pharmacy Times). Ballantyne said 87% of eligible participants chose to enroll, with approximately 4,200 patient-years of additional drug exposure and 500 participants treated for more than two years (Pharmacy Times).

    According to the interview, LDL reductions remained around 60%, and participants switching from placebo experienced a similar response after starting enlicitide (Pharmacy Times). Ballantyne also reported no newly emerging safety signals, although the article did not provide a detailed table of adverse-event rates (Pharmacy Times).

    These findings address a practical question: whether the cholesterol response persists with continued treatment. They are not, on their own, evidence that every patient will achieve the same reduction.

    Why an open-label result needs context

    The extension is different from a continuing blinded comparison against placebo, and the decision to enroll may select participants willing to remain in treatment (Pharmacy Times). In addition, about 10% to 15% of participants reportedly changed background therapy, including some reductions in statin or ezetimibe treatment (Pharmacy Times).

    Those changes complicate a simple interpretation of the longer-term figures. The results should be read as evidence about the treated extension population, not as proof that other cholesterol medicines are unnecessary.

    The outcome question remains separate

    The interview described a large, blinded cardiovascular outcomes trial as ongoing, with results not yet available to investigators (Pharmacy Times). That distinction matters because maintaining a lower LDL measurement and demonstrating fewer heart attacks or strokes are different study questions.

    For now, the update strengthens the reported durability story while leaving the cardiovascular outcome question open (Pharmacy Times). Future outcome results, rather than the extension alone, will be needed to establish what this particular medicine achieves beyond cholesterol lowering.

    FAQ

    Is enlicitide an approved medicine in the United States?

    The FDA’s 2026 approvals list records Lipfendra, or enlicitide decanoate, as approved on July 15, 2026, for LDL cholesterol reduction (FDA). The current prescribing information remains the appropriate reference for the complete approved conditions of use (FDA).

    Does this update prove that enlicitide prevents heart attacks?

    No cardiovascular outcome result was reported in this extension interview, and the dedicated outcomes trial was described as ongoing (Pharmacy Times). The news concerns sustained cholesterol lowering and additional safety exposure, not a completed demonstration of fewer heart attacks or strokes (Pharmacy Times).